Full Text
The Full Text of this article is available as a PDF (376.8 KB).
Figure 1.
No edge effect in NEW-SIRIUS: quantitative coronary angiography peri-stent analysis. Pooled data from the E- and C-SIRIUS trials, 8 months angiographic and 9 months clinical follow up.
Figure 2.
Inhibition of smooth muscle proliferation compared to control. Exposure time does not influence degree of inhibition. Reproduced with permission from Axel et al.7
Figure 3.
Good control of clinical effect of intimal hyperplasia with TAXUS stents irrespective of lesion length or reduction in vessel size. RVD, reference vessel diameter; TLR, target lesion revascularisation.
Figure 4.
Real world studies: the e-Cypher study status December 2004. Six months follow up: major adverse cardiac events (MACE).
Figure 5.
Real world studies: the e-Cypher study status December 2004. Patient subsets: 6 months target lesion revascularisation (TLR).
Figure 6.
Rapamycin: substitution of C-43 results in sirolimus analogues.
Figure 7.
The Conor drug eluting stent design.
Figure 8.
Endothelial progenitor cell technology.
Figure 9.
SIRIUS: mode of failure.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Axel D. I., Kunert W., Göggelmann C., Oberhoff M., Herdeg C., Küttner A., Wild D. H., Brehm B. R., Riessen R., Köveker G. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997 Jul 15;96(2):636–645. doi: 10.1161/01.cir.96.2.636. [DOI] [PubMed] [Google Scholar]
- Buellesfeld Lutz, Grube Eberhard. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts? Herz. 2004 Mar;29(2):167–170. doi: 10.1007/s00059-004-2557-5. [DOI] [PubMed] [Google Scholar]
- Colombo Antonio, Drzewiecki Janusz, Banning Adrian, Grube Eberhard, Hauptmann Karl, Silber Sigmund, Dudek Dariusz, Fort Stephen, Schiele Francois, Zmudka Krysztof. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003 Aug 4;108(7):788–794. doi: 10.1161/01.CIR.0000086926.62288.A6. [DOI] [PubMed] [Google Scholar]
- Gershlick Anthony, De Scheerder Ivan, Chevalier Bernard, Stephens-Lloyd Amanda, Camenzind Edoardo, Vrints Christian, Reifart Nicolaus, Missault Luc, Goy Jean-Jacques, Brinker Jeffrey A. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation. 2004 Jan 26;109(4):487–493. doi: 10.1161/01.CIR.0000109694.58299.A0. [DOI] [PubMed] [Google Scholar]
- Hong Myeong-Ki, Mintz Gary S., Lee Cheol Whan, Song Jong-Min, Han Ki-Hoon, Kang Duk-Hyun, Song Jae-Kwan, Kim Jae-Joong, Weissman Neil J., Fearnot Neal E. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation. 2003 Feb 4;107(4):517–520. doi: 10.1161/01.cir.0000054163.42072.d4. [DOI] [PubMed] [Google Scholar]
- Morice Marie-Claude, Serruys Patrick W., Sousa J. Eduardo, Fajadet Jean, Ban Hayashi Ernesto, Perin Marco, Colombo Antonio, Schuler G., Barragan Paul, Guagliumi Giulio. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002 Jun 6;346(23):1773–1780. doi: 10.1056/NEJMoa012843. [DOI] [PubMed] [Google Scholar]
- Moses Jeffrey W., Leon Martin B., Popma Jeffrey J., Fitzgerald Peter J., Holmes David R., O'Shaughnessy Charles, Caputo Ronald P., Kereiakes Dean J., Williams David O., Teirstein Paul S. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 Oct 2;349(14):1315–1323. doi: 10.1056/NEJMoa035071. [DOI] [PubMed] [Google Scholar]
- Schampaert Erick, Cohen Eric A., Schlüter Michael, Reeves François, Traboulsi Mouhieddin, Title Lawrence M., Kuntz Richard E., Popma Jeffrey J., C-SIRIUS Investigators The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004 Mar 17;43(6):1110–1115. doi: 10.1016/j.jacc.2004.01.024. [DOI] [PubMed] [Google Scholar]
- Schofer Joachim, Schlüter Michael, Gershlick Anthony H., Wijns William, Garcia Eulogio, Schampaert Erick, Breithardt Günter, E-SIRIUS Investigators Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003 Oct 4;362(9390):1093–1099. doi: 10.1016/S0140-6736(03)14462-5. [DOI] [PubMed] [Google Scholar]
- Serruys P. W., Unger F., van Hout B. A., van den Brand M. J., van Herwerden L. A., van Es G. A., Bonnier J. J., Simon R., Cremer J., Colombo A. The ARTS study (Arterial Revascularization Therapies Study). Semin Interv Cardiol. 1999 Dec;4(4):209–219. doi: 10.1006/siic.1999.0107. [DOI] [PubMed] [Google Scholar]